Loading...
Loading...
Browse all stories on DeepNewz
VisitWhat type of cancer will Vesta target next by May 30, 2025?
Breast Cancer • 25%
Lung Cancer • 25%
Prostate Cancer • 25%
Colorectal Cancer • 25%
Official announcements or press releases from Valar Labs
Valar Labs Secures $22M Series A for AI-Powered Cancer Tool Vesta
May 30, 2024, 04:07 PM
Valar Labs has launched an AI-powered cancer care prediction tool, Vesta, aimed at predicting treatment responses in bladder cancer. The biotech startup secured $22 million in a Series A funding round led by DCVC and a16z. The tool can scan digital histology slices from tumors to predict disease progression and treatment outcomes, potentially saving time for patients. Valar Labs plans to expand the application of this tool to other types of cancer. The company has rolled out its first test and notes that there are roughly 2 million new cancer diagnoses annually in the US alone.
View original story